Horisberger B, Gratwohl A, Baldomero H, Schmid C, Passweg J; International Society of Technology Assessment in Health Care. Meeting.

Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 2002; 18: abstract no. 139.

FMiG, St. Leonhard-Strasse 4, St. Gallen, Bruno.Horisberger@fhsg.ch; caroline.schmid@fhsg.ch

BACKGROUND/OBJECTIVES: Transplantation of hematopoetic stem cells (HSCT) is established therapy. Major changes have occurred during the last decade. Variations in a high cost medical field present a challenge to health care systems. Information on current use, trends and possibly predictions for the immediate future are warranted for treating physicians, patients and health care providers. METHODS: Data on 132,963 patients, 44,165 with an allogeneic HSCT (33%) and 88,798 with an autologous HSCT (67%), collected prospectively from 619 centres of the European Group for Blood and Marrow Transplantation (EBMT) and associated teams in 35 European countries between 1990 (4,234 HSCT) and 2000 (19,136 HSCT). Selected data from nine countries with at least 100 transplants per year were used to calculate weighted transplant rates (numbers of HSCT per ten million inhabitants) for each disease indication and transplant rates for the immediate future. RESULTS: Annual numbers of HSCT increased in all European countries and for all indications during the last decade. There were major differences in absolute transplant rates and in increase over time depending on disease indication and donor type. Transplant rates varied from <1 for some rare indications to 37.7 +/- 4.1 per ten million for acute myeloid leukemia in allogeneic HSCT or 95.5 +/- 13.5 per ten million for Non Hodgkin's lymphoma in autologous HSCT. Patterns of change over time vary. Projections predict a continuing increase in allogeneic HSCT for all indications except chronic myeloid leukemia. In autologous HSCT they predict a continuing increase for lymphoproliferative disorders, acute myeloid leukemia, myelodysplastic syndromes and some solid tumors but a decrease for most solid tumors. DISCUSSION: The report reveals changes during the last decade and reflects current status of HSCT in Europe. Transplant rates for the next few years can be predicted with reasonable probability for most disease indications. Despite marked changes in a rapidly evolving field, these data form a rational basis for patient counselling and health care planning.

Publication Types:

• Meeting Abstracts

Keywords:

• Bone Marrow Transplantation
• Cord Blood Stem Cell Transplantation
• Delivery of Health Care
• Demography
• Europe
• Forecasting
• Hematopoietic Stem Cell Transplantation
• Humans
• Leukemia, Myeloid, Acute
• Lymphoproliferative Disorders
• Neoplasms
• Peripheral Blood Stem Cell Transplantation
• Stem Cell Transplantation
• Tissue Donors
• Transplantation Conditioning
• Transplantation, Autologous
• Transplantation, Homologous
• surgery
• therapy
• transplantation
• hsrmtgs

Other ID:

• GWHSR0003076

UI: 102274755

From Meeting Abstracts